Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.

2024年10月29日 · Raptiva is used to treat plaque psoriasis (raised, silvery flaking of the skin) in adults. Raptiva may also be used for other purposes not listed in this medication guide. Raptiva increases the risk of serious infections, including a viral infection of the brain that can lead to disability or death.

Today, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market.

依法利珠单抗（ Efalizumab ，藥品商品名為 Raptiva，瑞體膚，默克）是牛皮癬的治療用藥，是一種抗CD11a的單株抗體製劑，其作用機制是辨識白血球上的CD11a抗原，使白血球與其他細胞附著的能力降低，抑制其免疫作用。

Over the next several months, healthcare providers will be transitioning patients with psoriasis currently using Raptiva to alternate treatments. Healthcare providers are being asked to not...

依法利珠单抗 （Efalizumab，药品商品名为 Raptiva，瑞体肤， 默克）是 牛皮癣 的治疗用药，是一种抗CD11a的 单株抗体 制剂，其作用机制是辨识 白血球 上的CD11a 抗原，使白血球与其他 细胞 附着的能力降低，抑制其 免疫 作用。 因为依法利珠单抗会抑制 免疫系统，所以其引发的 副作用 包括 细菌 性 败血症 、 病毒性脑膜炎， 真菌 性疾病，或因再 活化 的潜伏性JC 病毒 引发渐进性多病灶 脑白质病 (Progressive multifocal leukoencephalopathy, PML)。 [1]

RAPTIVA increases the risk for PML, a rapidly progressive viral infection of the central nervous system that has no known treatment and that leads to death or severe disability.

2022年8月11日 · RAPTIVA® (efalizumab) is an immunosuppressive recombinant humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

Raptiva（efalizumab）是一种类似于人抗体的人为形式的蛋白质。依法利珠单抗只能靶向并破坏体内的某些细胞。这可能有助于保护健康的细胞免受损害。 Raptiva用于治疗成人斑块状牛皮癣（皮肤隆起，银色剥落）。 Raptiva也可用于本药物指南中未列出的其他目的。

2010年2月7日 · Discover the latest news about our company, our products, our policies, and our people.